Posted by Michael Wonder on 13 Jan 2023
Tezspire approved for self-administration in the EU in a new pre-filled pen
13 January 2023 - New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations.
AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion from the EMA’s CHMP for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
The CHMP opinion can be implemented without the need for a European Commission decision due to the nature of the type-II label variation.
